Literature DB >> 31626711

High Plasma Erythropoietin Predicts Incident Fractures in Elderly Men with Normal Renal Function: The MrOS Sweden Cohort.

Hallgerdur Lind Kristjansdottir1, Catharina Lewerin1, Ulf H Lerner2, Hans Herlitz3, Peter Johansson1, Helena Johansson4,5, Magnus Karlsson6, Mattias Lorentzon4,7,8, Claes Ohlsson2, Östen Ljunggren9, Dan Mellström2,7,8.   

Abstract

Preclinical studies on the role of erythropoietin (EPO) in bone metabolism are contradictory. Regeneration models indicate an anabolic effect on bone healing, whereas models on physiologic bone remodeling indicate a catabolic effect on bone mass. No human studies on EPO and fracture risk are available. It is known that fibroblast growth factor 23 (FGF23) affects bone mineralization and that serum concentration of FGF23 is higher in men with decreased estimated glomerular filtration rate (eGFR). Recently, a direct association between EPO and FGF23 has been shown. We have explored the potential association between EPO and bone mineral density (BMD), fracture risk, and FGF23 in humans. Plasma levels of EPO were analyzed in 999 men (aged 69 to 81 years), participating in the Gothenburg part of the population-based Osteoporotic Fractures in Men (MrOS) study, MrOS Sweden. The mean ± SD EPO was 11.5 ± 9.0 IU/L. Results were stratified by eGFR 60 mL/min. For men with eGFR ≥60 mL/min (n = 728), EPO was associated with age (r = 0.13, p < 0.001), total hip BMD (r = 0.14, p < 0.001), intact (i)FGF23 (r = 0.11, p = 0.004), and osteocalcin (r = -0.09, p = 0.022). The association between total hip BMD and EPO was independent of age, body mass index (BMI), iFGF23, and hemoglobin (beta = 0.019, p < 0.001). During the 10-year follow-up, 164 men had an X-ray-verified fracture, including 117 major osteoporotic fractures (MOF), 39 hip fractures, and 64 vertebral fractures. High EPO was associated with higher risk for incident fractures (hazard ratio [HR] = 1.43 per tertile EPO, 95% confidence interval [CI] 1.35-1.63), MOF (HR = 1.40 per tertile EPO, 95% CI 1.08-1.82), and vertebral fractures (HR = 1.42 per tertile EPO, 95% CI 1.00-2.01) in a fully adjusted Cox regression model. In men with eGFR<60 mL/min, no association was found between EPO and BMD or fracture risk. We here demonstrate that high levels of EPO are associated with increased fracture risk and increased BMD in elderly men with normal renal function.
© 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BMD; ELDERLY MEN; ENDOGENOUS ERYTHROPOIETIN; FGF23; FRACTURES

Mesh:

Substances:

Year:  2019        PMID: 31626711     DOI: 10.1002/jbmr.3900

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  7 in total

1.  Anemia is associated with increased risk of non-vertebral osteoporotic fractures in elderly men: the MrOS Sweden cohort.

Authors:  Hallgerdur Lind Kristjansdottir; Dan Mellström; Peter Johansson; Magnus Karlsson; Liesbeth Vandenput; Mattias Lorentzon; Hans Herlitz; Claes Ohlsson; Ulf H Lerner; Catharina Lewerin
Journal:  Arch Osteoporos       Date:  2022-06-23       Impact factor: 2.879

2.  Erythropoietin Mediated Bone Loss in Mice Is Dose-Dependent and Mostly Irreversible.

Authors:  Albert Kolomansky; Sahar Hiram-Bab; Nathalie Ben-Califa; Tamar Liron; Naamit Deshet-Unger; Moshe Mittelman; Howard S Oster; Martina Rauner; Ben Wielockx; Drorit Neumann; Yankel Gabet
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

Review 3.  Effects of Erythropoietin in White Adipose Tissue and Bone Microenvironment.

Authors:  Sukanya Suresh; Jeeyoung Lee; Constance Tom Noguchi
Journal:  Front Cell Dev Biol       Date:  2020-11-24

4.  The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice.

Authors:  Zamzam Awida; Almog Bachar; Hussam Saed; Anton Gorodov; Nathalie Ben-Califa; Maria Ibrahim; Albert Kolomansky; Jennifer Ana Iden; Liad Graniewitz Visacovsky; Tamar Liron; Sahar Hiram-Bab; Michael Brines; Yankel Gabet; Drorit Neumann
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

5.  Erythropoietin Receptor (EPOR) Signaling in the Osteoclast Lineage Contributes to EPO-Induced Bone Loss in Mice.

Authors:  Zamzam Awida; Sahar Hiram-Bab; Almog Bachar; Hussam Saed; Dan Zyc; Anton Gorodov; Nathalie Ben-Califa; Sewar Omari; Jana Omar; Liana Younis; Jennifer Ana Iden; Liad Graniewitz Visacovsky; Ida Gluzman; Tamar Liron; Bitya Raphael-Mizrahi; Albert Kolomansky; Martina Rauner; Ben Wielockx; Yankel Gabet; Drorit Neumann
Journal:  Int J Mol Sci       Date:  2022-10-10       Impact factor: 6.208

6.  Erythropoietin in bone homeostasis-Implications for efficacious anemia therapy.

Authors:  Katrina M Lappin; Ken I Mills; Terence R Lappin
Journal:  Stem Cells Transl Med       Date:  2021-01-21       Impact factor: 6.940

7.  Erythropoietin signaling in osteoblasts is required for normal bone formation and for bone loss during erythropoietin-stimulated erythropoiesis.

Authors:  Sukanya Suresh; Jeeyoung Lee; Constance T Noguchi
Journal:  FASEB J       Date:  2020-07-15       Impact factor: 5.834

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.